BioCardia regains Nasdaq compliance after raising $7.35M through equity offerings

BioCardia, Inc.

Raised net proceeds of $0.7M (Apr), $0.5M (Jun), $5.1M (Sep public offer), and $1.0M from ATM sales (Apr–Sep 2025).
Believes stockholders' equity now exceeds the $2.5M minimum for continued listing under Nasdaq Rule 5550(b)(1).
Earlier Nasdaq extension to Sep 29, 2025; compliance will be monitored at next periodic report.
Warrants exercisable earlier of 2030 or PMDA approval of CardiAMP Cell Therapy System.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.